1
|
Singh N, Kulkarni GT, Kumar Y. Therapeutic Potential of Antileukotriene Drug- Camellia sinensis Extract Co-Formulation on Histamine Induced Asthma in Guinea Pigs. Curr Drug Res Rev 2021; 13:59-72. [PMID: 32787770 DOI: 10.2174/2589977512666200812151620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 05/07/2020] [Accepted: 06/29/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND/OBJECTIVE To study the therapeutic potential of Antileukotriene drug- Camellia sinensis extract co-formulation on histamine induced asthma in guinea pigs. METHODS SRSD of Montelukast sodium was prepared by the solvent evaporation method. Lyophilized aqueous extract of Camellia sinensis leaves and SRSD mixture was filled in capsule and the capsule shell was coated to achieve initial release lag time. In vitro and pharmacokinetic study of capsules was performed and compared with commercial tablets. A further role of green tea, as an antioxidant adjunct for asthma management, has been analyzed by lung histology, mast cell count and oxidative stress assay in the serum of control and experimental animals. RESULTS The drug release from the commercial tablet was immediate and rapid, but capsule has shown an initial 3.5 hr lag time followed by sustained action up to 8 hr. Pharmacokinetic results show that studied formulations are bioequivalent with respect to Cmax and AUC, while rest parameters showed asignificant difference. Mast cells count in lung tissue were increased (p<0.001) in the experimental group along with glycoprotein deposition in asthmatic bronchioles. Levels of SOD and GPX were decreased (p<0.05) while CAT was increased (p<0.04) in the asthma group in comparison to control. CONCLUSION In the experimental animal model, co-formulation was effective in modulating allergic inflammation and contributing to better control of the inflammatory response. Our findings suggest that Camellia sinensis leaves extract may be used as an adjunct for future improvements in asthma treatment and prevention.
Collapse
Affiliation(s)
- Neelam Singh
- Department of Pharmaceutics, ITS College of Pharmacy, NH-58, Ghaziabad 201206, India
| | - Giriraj T Kulkarni
- Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Uttar Pradesh, Sector 125, Noida, India
| | - Yatendra Kumar
- Department of Pharmaceutics, ITS College of Pharmacy, NH-58, Ghaziabad 201206, India
| |
Collapse
|
2
|
Kim DW, Kim YH, Yousaf AM, Kim DS, Kwon TK, Park JH, Kim YI, Park JH, Jin SG, Kim KS, Cho KH, Li DX, Kim JO, Yong CS, Woo JS, Choi HG. Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats. Arch Pharm Res 2016; 39:539-546. [PMID: 26983932 DOI: 10.1007/s12272-015-0664-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 09/22/2015] [Indexed: 12/23/2022]
Abstract
To develop a montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats, several montelukast sodium-loaded suspensions were prepared with a suspending agent, stabilizers and anti-aggregation agents, and their stabilities were investigated by visually observing the sedimentation phenomenon and determining the concentration of the degradation product. Moreover, dissolution and pharmacokinetic studies of the optimized formulation were examined in rats compared to commercial montelukast sodium-loaded granules. Avicel RC-591 (Avicel), a suspending agent, prevented the sedimentation of these suspensions at >2.496 (w/v) per cent composition. Amongst the stabilizers tested, fumaric acid provided the lowest concentration of montelukast sulphoxide (a degradation product) in these suspensions at 40 °C, demonstrating its excellent stabilizing activity. Furthermore, as an anti-aggregation agent, glycerin gave lower amounts of degradation product than those with poloxamer 407 and Tween 80. In particular, montelukast-loaded oral suspension, an aqueous suspension containing montelukast sodium/Avicel/fumaric acid/glycerin at a concentration of 312/2496/15.6/62.4 (mg/100 ml), and the commercial granules exhibited similar dissolution profiles in 0.5% (w/v) aqueous solution of sodium lauryl sulphate. Moreover, the pharmacokinetics in rats provided by this suspension was comparable to that of the commercial granules, suggesting that they were bioequivalent. In addition, it was physically and chemically stable at 40 °C for at least 6 months. Thus, this montelukast sodium-loaded oral suspension, with bioequivalence to the commercial granules and excellent stability, could be a prospective dosage form for the treatment of asthma.
Collapse
Affiliation(s)
- Dong Wuk Kim
- College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-Gu, Ansan, 426-791, South Korea
| | - Young Hun Kim
- College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-Gu, Ansan, 426-791, South Korea.,Pharmaceutical Research Centre, Hanmi Pharm. Co., Paltan-Myeon, 893-5, Hwaseong, Gyeonggi-Do, 445-913, South Korea
| | - Abid Mehmood Yousaf
- College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-Gu, Ansan, 426-791, South Korea
| | - Dong Shik Kim
- College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-Gu, Ansan, 426-791, South Korea
| | - Taek Kwan Kwon
- Pharmaceutical Research Centre, Hanmi Pharm. Co., Paltan-Myeon, 893-5, Hwaseong, Gyeonggi-Do, 445-913, South Korea
| | - Jung Hee Park
- Pharmaceutical Research Centre, Hanmi Pharm. Co., Paltan-Myeon, 893-5, Hwaseong, Gyeonggi-Do, 445-913, South Korea
| | - Yong Il Kim
- Pharmaceutical Research Centre, Hanmi Pharm. Co., Paltan-Myeon, 893-5, Hwaseong, Gyeonggi-Do, 445-913, South Korea
| | - Jae-Hyun Park
- Pharmaceutical Research Centre, Hanmi Pharm. Co., Paltan-Myeon, 893-5, Hwaseong, Gyeonggi-Do, 445-913, South Korea
| | - Sung Giu Jin
- College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-Gu, Ansan, 426-791, South Korea
| | - Kyung Soo Kim
- College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-Gu, Ansan, 426-791, South Korea
| | - Kwan Hyung Cho
- College of Pharmacy, Yeungnam University, 214-1, Dae-Dong, Gyongsan, 712-749, South Korea.,College of Pharmacy, Inje University, Inje-ro 197, Gimhae, 621-749, South Korea
| | - Dong Xun Li
- National Pharmaceutical Engineering Centre for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Traditional Chinese Medicine, 56 Yangming Road, Nanchang, Jiangxi, 330006, China
| | - Jong Oh Kim
- College of Pharmacy, Yeungnam University, 214-1, Dae-Dong, Gyongsan, 712-749, South Korea
| | - Chul Soon Yong
- College of Pharmacy, Yeungnam University, 214-1, Dae-Dong, Gyongsan, 712-749, South Korea
| | - Jong Soo Woo
- Pharmaceutical Research Centre, Hanmi Pharm. Co., Paltan-Myeon, 893-5, Hwaseong, Gyeonggi-Do, 445-913, South Korea.
| | - Han-Gon Choi
- College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-Gu, Ansan, 426-791, South Korea.
| |
Collapse
|
3
|
Zaid AN, Mousa A, Ghazal N, Bustami R. Interchangeability and comparative effectiveness between generic and brand montelukast immediate release tablets after a single oral administration in healthy volunteers. Clin Transl Allergy 2015; 5:37. [PMID: 26561521 PMCID: PMC4641366 DOI: 10.1186/s13601-015-0081-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Accepted: 10/16/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Montelukast is a leukotriene receptor antagonist. The release of leukotrienes causes narrowing and constricting in the respiratory airways. Blocking the action of these leukotrienes, montelukast can be used for the prophylaxis and treatment of chronic asthma. OBJECTIVE The aim of this study was to evaluate the interchangeability and comparative effectiveness between a generic and a brand montelukast 10 mg immediate release tablets (Broncast(®) and Singulair(®), respectively) after a single oral dose among Arab Mediterranean volunteers. METHODS An open-label, randomized two-period crossover bioequivalence design was conducted in 31 healthy male volunteers with a 1 week washout between each study period and under fasting conditions. The plasma drug concentration was assessed by using a previously validated LC MS/MS method. The ratio between the generic and brand of geometric least squares means was reported for both generic and brand products. Moreover, an in vitro dissolution study was conducted on generic and brand tablets using three different pH media, and similarity and non-similarity factors (f2 and f1) were calculated. RESULTS The used bioanalytical method was found to be linear within the range 6.098-365.855 ng/mL. The correlation coefficient was close to 0.999 during the course of the study validation. Statistical comparison of the main pharmacokinetic parameters showed the inexistence of any significant difference between generic and the brand. The point estimates (ratios of geometric means) were 111.939, 111.711, and 112.169 % for AUC0-24, AUC0-∞, and Cmax, respectively. The 90 % confidence intervals (CIs) were within the pre-defined limits of 80.00-125.00 % as specified by the FDA and EMA for bioequivalence studies. F2 and f1 were higher than 50 and lower than 15, respectively in all selected pH media. CONCLUSION Broncast(®) immediate release film coated tablets (10 mg/tablet) are bioequivalent to Singulair(®) immediate release film coated tablets (10 mg/tablet), with a comparable safety and efficacy profile. This suggests that these two formulations can be clinically considered interchangeable. The dissolution study suggests that it could be used as premarketing quality control parameter in order to maintain the high quality of the produced product.
Collapse
Affiliation(s)
- Abdel Naser Zaid
- Pharmaceutical Chemistry and Technology, Department of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, P.O.Box 7, Palestine
| | - Ayman Mousa
- R&D Department Avalon Pharma (Middle East Pharmaceutical Industries Co. Ltd), Riyadh, Kingdom of Saudi Arabia
| | | | | |
Collapse
|